Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2026-04-30 Proxy Solicitation & In…
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 10, 2026
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'Schedule 14A Information' and is a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is a definitive proxy statement for the 2026 annual meeting of shareholders of Lineage Cell Therapeutics, Inc. The content includes details about the meeting agenda, director nominations, voting instructions, and other proxy solicitation information. There is no financial data or report content, but rather materials prepared to solicit shareholder votes for the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains the full proxy statement, not just an announcement or notice, so it is not RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2026-04-30 Hebrew (modern)
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 10, 2026
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled as an 'Official notification to shareholders of matters to be brought to a vote ("Proxy")'. It references a report attached named 'First_Form_isa.pdf' and mentions it is an immediate report under Regulation 4 of the Securities Regulations. The content and metadata indicate this is a proxy solicitation document intended to inform shareholders about voting matters. The document length is short (1964 characters), and it is primarily a notification rather than a full report or financial statement. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2026-04-30 English
ARS - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
Annual Report
2026-04-29 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-29 English
DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
Lineage Announces Formation of Scientific Advisory Board
Board/Management Information Classification · 92% confidence The document is a press release announcing the formation of a Scientific Advisory Board and appointing a new Senior Vice President and Head of Clinical Operations. It focuses on management appointments and corporate governance changes, rather than financial results, regulatory filings, or investor presentations. This fits the definition of Board/Management Information (MANG).
2026-04-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.